Literature DB >> 22068385

Determinants of undercarboxylated and carboxylated osteocalcin concentrations in type 1 diabetes.

K M Thrailkill1, C-H Jo, G E Cockrell, C S Moreau, C K Lumpkin, J L Fowlkes.   

Abstract

UNLABELLED: To determine whether undercarboxylated osteocalcin (UC-OC) or gamma-carboxyglutamic-carboxylated-type osteocalcin (GLA-OC) concentrations deviate from normal in type 1 diabetes (T1D), serum levels were compared between 115 subjects with T1D and 55 age-matched healthy controls. UC-OC and GLA-OC concentrations were similar between groups; however, in T1D, UC-OC correlated positively with markers of insulin exposure, either endogenously produced or exogenously administered.
INTRODUCTION: A study was conducted to determine whether dysregulation of circulating concentrations of UC-OC or GLA-OC occurs in patients with type 1 diabetes, a condition of insulin deficiency without insulin resistance.
METHODS: We measured serum concentrations of UC-OC and GLA-OC in 115 subjects with T1D, ages 14-40 years, and in 55 age-matched healthy control subjects. Relationships between UC-OC and GLA-OC concentrations and patient characteristics (gender and age), indices of glycemic control (hemoglobin A1c (HbA1c), fasting plasma glucose, C-peptide concentration, 3-day average glucose measured by a continuous glucose sensor, total daily insulin dose) and circulating indices of skeletal homeostasis (total calcium, 25-OH vitamin D, parathyroid hormone, insulin-like growth factor 1 (IGF-1), type 1 collagen degradation fragments (CTX), adiponectin, leptin) were examined. Between group differences in the concentrations of UC-OC and GLA-OC were the main outcome measures.
RESULTS: Although adiponectin levels were higher in the T1D group, between-group comparisons did not reveal statistically significant differences in concentration of UC-OC, GLA-OC, CTX or leptin between the T1D and control populations. Instead, by multivariate regression modeling, UC-OC was correlated with younger age (p < 0.001), higher CTX (p < 0.001), lower HbA1c (p = 0.013), and higher IGF-1 (p = 0.086). Moreover, within the T1D subgroup, UC-OC was positively correlated with C-peptide/glucose ratio (reflecting endogenous insulin secretion), with IGF-1 (reflecting intra-portal insulin sufficiency), and with total daily insulin dose.
CONCLUSIONS: In T1D, UC-OC appears to correlate positively with markers of insulin exposure, either endogenously produced or exogenously administered.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22068385      PMCID: PMC3471372          DOI: 10.1007/s00198-011-1807-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  34 in total

1.  The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study.

Authors:  Angela D Liese; Ralph B D'Agostino; Richard F Hamman; Patrick D Kilgo; Jean M Lawrence; Lenna L Liu; Beth Loots; Barbara Linder; Santica Marcovina; Beatriz Rodriguez; Debra Standiford; Desmond E Williams
Journal:  Pediatrics       Date:  2006-10       Impact factor: 7.124

2.  Biochemical markers of bone cell activity in children with type 1 diabetes mellitus.

Authors:  Agnieszka Pater; Grazyna Sypniewska; Olgierd Pilecki
Journal:  J Pediatr Endocrinol Metab       Date:  2010 Jan-Feb       Impact factor: 1.634

Review 3.  Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility.

Authors:  K M Thrailkill
Journal:  Diabetes Technol Ther       Date:  2000       Impact factor: 6.118

4.  Foxo1 mediates insulin-like growth factor 1 (IGF1)/insulin regulation of osteocalcin expression by antagonizing Runx2 in osteoblasts.

Authors:  Shengyong Yang; Haiyan Xu; Shibing Yu; Huiling Cao; Jie Fan; Chunxi Ge; Renny T Fransceschi; Henry H Dong; Guozhi Xiao
Journal:  J Biol Chem       Date:  2011-04-06       Impact factor: 5.157

5.  Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis.

Authors:  P Szulc; P D Delmas
Journal:  Osteoporos Int       Date:  2008-07-16       Impact factor: 4.507

6.  Matrix metalloproteinase-2 dysregulation in type 1 diabetes.

Authors:  Kathryn M Thrailkill; Robert C Bunn; Cynthia S Moreau; Gael E Cockrell; Pippa M Simpson; Hannah N Coleman; J Paul Frindik; Stephen F Kemp; John L Fowlkes
Journal:  Diabetes Care       Date:  2007-06-11       Impact factor: 19.112

7.  Elevated levels of high-molecular-weight adiponectin in type 1 diabetes.

Authors:  Henrik Leth; Kristian K Andersen; Jan Frystyk; Lise Tarnow; Peter Rossing; Hans-Henrik Parving; Allan Flyvbjerg
Journal:  J Clin Endocrinol Metab       Date:  2008-05-27       Impact factor: 5.958

8.  Determinants and correlates of serum undercarboxylated osteocalcin.

Authors:  Katharina Nimptsch; Susanne Hailer; Sabine Rohrmann; Kurt Gedrich; Gunther Wolfram; Jakob Linseisen
Journal:  Ann Nutr Metab       Date:  2008-01-28       Impact factor: 3.374

9.  Endocrine regulation of energy metabolism by the skeleton.

Authors:  Na Kyung Lee; Hideaki Sowa; Eiichi Hinoi; Mathieu Ferron; Jong Deok Ahn; Cyrille Confavreux; Romain Dacquin; Patrick J Mee; Marc D McKee; Dae Young Jung; Zhiyou Zhang; Jason K Kim; Franck Mauvais-Jarvis; Patricia Ducy; Gerard Karsenty
Journal:  Cell       Date:  2007-08-10       Impact factor: 41.582

10.  The association between adiponectin/leptin ratio and diabetes type: the SEARCH for Diabetes in Youth Study.

Authors:  David M Maahs; Richard F Hamman; Ralph D'Agostino; Lawrence M Dolan; Guiseppina Imperatore; Jean M Lawrence; Santica M Marcovina; Elizabeth J Mayer-Davis; Catherine Pihoker; Dana Dabelea
Journal:  J Pediatr       Date:  2009-07       Impact factor: 4.406

View more
  19 in total

1.  Osteocalcin levels are inversely associated with Hba1c and BMI in adult subjects with long-standing type 1 diabetes.

Authors:  Ernesto Maddaloni; Luca D'Onofrio; Angelo Lauria; Anna Rita Maurizi; Rocky Strollo; Andrea Palermo; Nicola Napoli; Silvia Angeletti; Paolo Pozzilli; Silvia Manfrini
Journal:  J Endocrinol Invest       Date:  2014-05-24       Impact factor: 4.256

Review 2.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

Review 3.  The Endocrine Role of Bone in Cardiometabolic Health.

Authors:  Rosemary DeLuccia; May Cheung; Rohit Ramadoss; Abeer Aljahdali; Deeptha Sukumar
Journal:  Curr Nutr Rep       Date:  2019-09

Review 4.  Epidemiology of Skeletal Health in Type 1 Diabetes.

Authors:  David R Weber; George Schwartz
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

5.  Osteo-promoting effects of insulin-like growth factor I (IGF-I) in a mouse model of type 1 diabetes.

Authors:  John L Fowlkes; Jeffry S Nyman; R Clay Bunn; Chanhee Jo; Elizabeth C Wahl; Lichu Liu; Gael E Cockrell; Lindsey M Morris; Charles K Lumpkin; Kathryn M Thrailkill
Journal:  Bone       Date:  2013-07-23       Impact factor: 4.398

6.  The role of vitamin D in the metabolic homeostasis of diabetic bone.

Authors:  Kathryn M Thrailkill; John L Fowlkes
Journal:  Clin Rev Bone Miner Metab       Date:  2013-03-01

7.  Pleotropic Acute and Chronic Effects of Leptin to Reverse Type 1 Diabetes.

Authors:  Rachel J Perry
Journal:  Postdoc J       Date:  2017-01

8.  In vivo analysis of the contribution of bone resorption to the control of glucose metabolism in mice.

Authors:  Julie Lacombe; Gerard Karsenty; Mathieu Ferron
Journal:  Mol Metab       Date:  2013-08-15       Impact factor: 7.422

9.  Contributions of the Insulin/Insulin-Like Growth Factor-1 Axis to Diabetic Osteopathy.

Authors:  John L Fowlkes; Clay Bunn R; Kathryn M Thrailkill
Journal:  J Diabetes Metab       Date:  2011-11-25

10.  Effect of calcitriol on bone turnover and osteocalcin in recent-onset type 1 diabetes.

Authors:  Nicola Napoli; Rocky Strollo; Dario Pitocco; Carla Bizzarri; Ernesto Maddaloni; Daria Maggi; Silvia Manfrini; Ann Schwartz; Paolo Pozzilli
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.